BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lu D, Ni Z, Liu X, Feng S, Dong X, Shi X, Zhai J, Mai S, Jiang J, Wang Z, Wu H, Cai K. Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages. J Immunol Res 2019;2019:1919082. [PMID: 31781673 DOI: 10.1155/2019/1919082] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Segovia-Mendoza M, Romero-Garcia S, Lemini C, Prado-Garcia H. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation. J Immunol Res 2021;2021:6668573. [PMID: 33506060 DOI: 10.1155/2021/6668573] [Reference Citation Analysis]
2 Yeo ECF, Brown MP, Gargett T, Ebert LM. The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy. Cells 2021;10:607. [PMID: 33803414 DOI: 10.3390/cells10030607] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Lopez-Yrigoyen M, Cassetta L, Pollard JW. Macrophage targeting in cancer. Ann N Y Acad Sci 2021;1499:18-41. [PMID: 32445205 DOI: 10.1111/nyas.14377] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
4 Matsuda Y, Watanabe T, Li XK. Approaches for Controlling Antibody-Mediated Allograft Rejection Through Targeting B Cells. Front Immunol 2021;12:682334. [PMID: 34276669 DOI: 10.3389/fimmu.2021.682334] [Reference Citation Analysis]
5 Bailly C. The implication of the PD-1/PD-L1 checkpoint in chronic periodontitis suggests novel therapeutic opportunities with natural products. Jpn Dent Sci Rev 2020;56:90-6. [PMID: 32612718 DOI: 10.1016/j.jdsr.2020.04.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
6 Erkhem-Ochir B, Tatsuishi W, Yokobori T, Gombodorj N, Saeki H, Shirabe K, Abe T. Immunohistochemical Detection of Bacteria in the Resected Valves was Associated with Stromal Immune Checkpoint Protein Expression that may Contribute to Calcific Aortic Stenosis. Semin Thorac Cardiovasc Surg 2021:S1043-0679(21)00466-4. [PMID: 34688900 DOI: 10.1053/j.semtcvs.2021.10.007] [Reference Citation Analysis]
7 Wu B, Chiang HC, Sun X, Yuan B, Mitra P, Hu Y, Curiel TJ, Li R. Genetic ablation of adipocyte PD-L1 reduces tumor growth but accentuates obesity-associated inflammation. J Immunother Cancer 2020;8:e000964. [PMID: 32817394 DOI: 10.1136/jitc-2020-000964] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
8 Tobin JWD, Bednarska K, Campbell A, Keane C. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma. Cells 2021;10:1152. [PMID: 34068762 DOI: 10.3390/cells10051152] [Reference Citation Analysis]
9 Costa AC, Santos JMO, Gil da Costa RM, Medeiros R. Impact of immune cells on the hallmarks of cancer: A literature review. Crit Rev Oncol Hematol 2021;168:103541. [PMID: 34801696 DOI: 10.1016/j.critrevonc.2021.103541] [Reference Citation Analysis]
10 Li CM, Shapiro H, Tsiobikas C, Selfors LM, Chen H, Rosenbluth J, Moore K, Gupta KP, Gray GK, Oren Y, Steinbaugh MJ, Guerriero JL, Pinello L, Regev A, Brugge JS. Aging-Associated Alterations in Mammary Epithelia and Stroma Revealed by Single-Cell RNA Sequencing. Cell Rep 2020;33:108566. [PMID: 33378681 DOI: 10.1016/j.celrep.2020.108566] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
11 Deshpande RP, Sharma S, Watabe K. The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors. Cancers (Basel) 2020;12:E2983. [PMID: 33076303 DOI: 10.3390/cancers12102983] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Pagkopoulou E, Simopoulou T, Maragkouli E, Perifanou-Sotiri S, Kotsakis A, Bogdanos DP. Arthritis and Myositis in a Patient Treated with Programmed Cell Death-1 (PD-1) Inhibitor Pembrolizumab for Lung Cancer. Mediterr J Rheumatol 2020;31:355-7. [PMID: 33163870 DOI: 10.31138/mjr.31.3.355] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Gusak A, Fedorova L, Lepik K, Volkov N, Popova M, Moiseev I, Mikhailova N, Baykov V, Kulagin A. Immunosuppressive Microenvironment and Efficacy of PD-1 Inhibitors in Relapsed/Refractory Classic Hodgkin Lymphoma: Checkpoint Molecules Landscape and Macrophage Populations. Cancers (Basel) 2021;13:5676. [PMID: 34830831 DOI: 10.3390/cancers13225676] [Reference Citation Analysis]
14 Matsuda Y, Hiramitsu T, Li XK, Watanabe T. Characteristics of Immunoglobulin M Type Antibodies of Different Origins from the Immunologic and Clinical Viewpoints and Their Application in Controlling Antibody-Mediated Allograft Rejection. Pathogens 2020;10:4. [PMID: 33374617 DOI: 10.3390/pathogens10010004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Aminin D, Wang YM. Macrophages as a "weapon" in anticancer cellular immunotherapy. Kaohsiung J Med Sci 2021;37:749-58. [PMID: 34110692 DOI: 10.1002/kjm2.12405] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Ozawa H, Imazeki H, Ogiwara Y, Kawakubo H, Fukuda K, Kitagawa Y, Kudo-Saito C. Targeting AURKA in treatment of peritoneal tumor dissemination in gastrointestinal cancer. Transl Oncol 2021;16:101307. [PMID: 34902741 DOI: 10.1016/j.tranon.2021.101307] [Reference Citation Analysis]
17 Hamilton JAG, Lee MY, Hunter R, Ank RS, Story JY, Talekar G, Sisroe T, Ballak DB, Fedanov A, Porter CC, Eisenmesser EZ, Dinarello CA, Raikar SS, DeGregori J, Henry CJ. Interleukin-37 improves T-cell-mediated immunity and chimeric antigen receptor T-cell therapy in aged backgrounds. Aging Cell 2021;20:e13309. [PMID: 33480151 DOI: 10.1111/acel.13309] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Zhou X, Liu X, Huang L. Macrophage-Mediated Tumor Cell Phagocytosis: Opportunity for Nanomedicine Intervention. Adv Funct Mater 2021;31:2006220. [PMID: 33692665 DOI: 10.1002/adfm.202006220] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
19 Mojsilovic SS, Mojsilovic S, Villar VH, Santibanez JF. The Metabolic Features of Tumor-Associated Macrophages: Opportunities for Immunotherapy? Anal Cell Pathol (Amst) 2021;2021:5523055. [PMID: 34476174 DOI: 10.1155/2021/5523055] [Reference Citation Analysis]
20 Fan TW, Higashi RM, Song H, Daneshmandi S, Mahan AL, Purdom MS, Bocklage TJ, Pittman TA, He D, Wang C, Lane AN. Innate immune activation by checkpoint inhibition in human patient-derived lung cancer tissues. Elife 2021;10:e69578. [PMID: 34406120 DOI: 10.7554/eLife.69578] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Han BW, Yang X, Qu SF, Guo ZW, Huang LM, Li K, Ouyang GJ, Cai GX, Xiao WW, Weng RT, Xu S, Huang J, Yang XX, Wu YS. A Deep-Learning Pipeline for TSS Coverage Imputation From Shallow Cell-Free DNA Sequencing. Front Med (Lausanne) 2021;8:684238. [PMID: 34926480 DOI: 10.3389/fmed.2021.684238] [Reference Citation Analysis]
22 Patil S, Sayed ME, Mugri MH, Alsharif KF, Salman A, Bhandi S, Baeshen HA, Balaji TM, Yadalam PK, Varadarajan S, Radha RSR, Awan KH, Patil VR, Raj AT. Allicin May Promote Reversal of T-Cell Dysfunction in Periodontitis via the PD-1 Pathway. Int J Mol Sci 2021;22:9162. [PMID: 34502071 DOI: 10.3390/ijms22179162] [Reference Citation Analysis]
23 Davis-Marcisak EF, Fitzgerald AA, Kessler MD, Danilova L, Jaffee EM, Zaidi N, Weiner LM, Fertig EJ. Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors. Genome Med 2021;13:129. [PMID: 34376232 DOI: 10.1186/s13073-021-00944-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Singh V, Khurana A, Allawadhi P, Banothu AK, Bharani KK, Weiskirchen R. Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases. Front Pharmacol 2021;12:790963. [PMID: 35002724 DOI: 10.3389/fphar.2021.790963] [Reference Citation Analysis]
25 Liu J, Yang DC, Zhang J, Hsu SW, Weiss RH, Chen CH. A Novel Renoprotective Strategy: Upregulation of PD-L1 Mitigates Cisplatin-Induced Acute Kidney Injury. Int J Mol Sci 2021;22:13304. [PMID: 34948109 DOI: 10.3390/ijms222413304] [Reference Citation Analysis]
26 Fattore L, Ruggiero CF, Liguoro D, Castaldo V, Catizone A, Ciliberto G, Mancini R. The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma. Front Oncol 2021;11:645069. [PMID: 33816298 DOI: 10.3389/fonc.2021.645069] [Reference Citation Analysis]
27 Chamseddine AN, Assi T, Mir O, Chouaib S. Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. Pharmacol Ther 2021;:107986. [PMID: 34481812 DOI: 10.1016/j.pharmthera.2021.107986] [Reference Citation Analysis]
28 Hossain SM, Lynch-sutherland CF, Chatterjee A, Macaulay EC, Eccles MR. Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance? Epigenomes 2021;5:16. [DOI: 10.3390/epigenomes5030016] [Reference Citation Analysis]
29 Zhou L, Matsushima GK. Tyro3, Axl, Mertk receptor-mediated efferocytosis and immune regulation in the tumor environment. Int Rev Cell Mol Biol 2021;361:165-210. [PMID: 34074493 DOI: 10.1016/bs.ircmb.2021.02.002] [Reference Citation Analysis]
30 Khononov I, Jacob E, Fremder E, Dahan N, Harel M, Raviv Z, Krastev B, Shaked Y. Host response to immune checkpoint inhibitors contributes to tumor aggressiveness. J Immunother Cancer 2021;9:e001996. [PMID: 33707313 DOI: 10.1136/jitc-2020-001996] [Reference Citation Analysis]
31 Ma B, Akosman B, Kamle S, Lee CM, He CH, Koo JS, Lee CG, Elias JA. CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses. J Clin Invest 2021;131:e137750. [PMID: 34720089 DOI: 10.1172/JCI137750] [Reference Citation Analysis]
32 Jain P, Kathuria H, Momin M. Clinical therapies and nano drug delivery systems for urinary bladder cancer. Pharmacol Ther 2021;226:107871. [PMID: 33915179 DOI: 10.1016/j.pharmthera.2021.107871] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Bao C, Gao Q, Li LL, Han L, Zhang B, Ding Y, Song Z, Zhang R, Zhang J, Wu XH. The Application of Nanobody in CAR-T Therapy. Biomolecules 2021;11:238. [PMID: 33567640 DOI: 10.3390/biom11020238] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
34 Kong F, Sun K, Zhu J, Li F, Lin F, Sun X, Luo X, Ren C, Lu L, Zhao S, Sun J, Wang Y, Shi J. PD-L1 Improves Motor Function and Alleviates Neuropathic Pain in Male Mice After Spinal Cord Injury by Inhibiting MAPK Pathway. Front Immunol 2021;12:670646. [PMID: 33936116 DOI: 10.3389/fimmu.2021.670646] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Xiao Y, Zhang L, Zhu J, Zhang Y, Yang R, Yan J, Huang R, Zheng C, Xiao W, Huang C, Wang Y. Predicting the herbal medicine triggering innate anti-tumor immunity from a system pharmacology perspective. Biomed Pharmacother 2021;143:112105. [PMID: 34560533 DOI: 10.1016/j.biopha.2021.112105] [Reference Citation Analysis]
36 Zhao J, Roberts A, Wang Z, Savage J, Ji RR. Emerging Role of PD-1 in the Central Nervous System and Brain Diseases. Neurosci Bull 2021;37:1188-202. [PMID: 33877518 DOI: 10.1007/s12264-021-00683-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Díaz-Montero CM, Rini BI, Finke JH. The immunology of renal cell carcinoma. Nat Rev Nephrol 2020;16:721-35. [PMID: 32733094 DOI: 10.1038/s41581-020-0316-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
38 Xu HZ, Li TF, Wang C, Ma Y, Liu Y, Zheng MY, Liu ZJ, Chen JB, Li K, Sun SK, Komatsu N, Xu YH, Zhao L, Chen X. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells. J Nanobiotechnology 2021;19:268. [PMID: 34488792 DOI: 10.1186/s12951-021-01017-w] [Reference Citation Analysis]
39 Allouch S, Malki A, Allouch A, Gupta I, Vranic S, Al Moustafa AE. High-Risk HPV Oncoproteins and PD-1/PD-L1 Interplay in Human Cervical Cancer: Recent Evidence and Future Directions. Front Oncol 2020;10:914. [PMID: 32695664 DOI: 10.3389/fonc.2020.00914] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Zhang XL, Hu LP, Yang Q, Qin WT, Wang X, Xu CJ, Tian GA, Yang XM, Yao LL, Zhu L, Nie HZ, Li Q, Xu Q, Zhang ZG, Zhang YL, Li J, Wang YH, Jiang SH. CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-β receptors in colorectal cancer. Oncogene 2021;40:3959-73. [PMID: 33986509 DOI: 10.1038/s41388-021-01827-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Veluswamy P, Wacker M, Scherner M, Wippermann J. Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance. Int J Mol Sci 2020;21:E8159. [PMID: 33142805 DOI: 10.3390/ijms21218159] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
42 Ramesh A, Malik V, Ranjani HA, Smith H, Kulkarni AA. Rational combination of an immune checkpoint inhibitor with CSF1R inhibitor-loaded nanoparticle enhances anticancer efficacy. Drug Deliv Transl Res 2021. [PMID: 34365577 DOI: 10.1007/s13346-021-01040-2] [Reference Citation Analysis]
43 Calero-Pérez P, Wu S, Arús C, Candiota AP. Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses. Cancers (Basel) 2021;13:2663. [PMID: 34071393 DOI: 10.3390/cancers13112663] [Reference Citation Analysis]
44 Lai CY, Tseng PC, Chen CL, Satria RD, Wang YT, Lin CF. Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages. J Inflamm Res 2021;14:5241-9. [PMID: 34675601 DOI: 10.2147/JIR.S329921] [Reference Citation Analysis]
45 Lenouvel D, González-Moles MÁ, Ruiz-Ávila I, Chamorro-Santos C, González-Ruiz L, González-Ruiz I, Ramos-García P. Clinicopathological and prognostic significance of PD-L1 in oral cancer: A preliminary retrospective immunohistochemistry study. Oral Dis 2021;27:173-82. [PMID: 32583572 DOI: 10.1111/odi.13509] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
46 Davidsson S, Carlsson J, Greenberg L, Wijkander J, Söderquist B, Erlandsson A. Cutibacterium acnes Induces the Expression of Immunosuppressive Genes in Macrophages and is Associated with an Increase of Regulatory T-Cells in Prostate Cancer. Microbiol Spectr 2021;9:e0149721. [PMID: 34937192 DOI: 10.1128/spectrum.01497-21] [Reference Citation Analysis]
47 Li X, Zhu S, Yin P, Zhang S, Xu J, Zhang Q, Shi S, Zhang T. Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and therapeutic effects. Drug Deliv 2021;28:1849-60. [PMID: 34515617 DOI: 10.1080/10717544.2021.1971797] [Reference Citation Analysis]
48 Guillot A, Guerri L, Feng D, Kim SJ, Ahmed YA, Paloczi J, He Y, Schuebel K, Dai S, Liu F, Pacher P, Kisseleva T, Qin X, Goldman D, Tacke F, Gao B. Bile acid-activated macrophages promote biliary epithelial cell proliferation through integrin αvβ6 upregulation following liver injury. J Clin Invest 2021;131:132305. [PMID: 33724957 DOI: 10.1172/JCI132305] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]